HC Wainwright Issues Positive Outlook for PTGX Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Equities research analysts at HC Wainwright raised their Q2 2026 EPS estimates for shares of Protagonist Therapeutics in a research note issued to investors on Monday, May 18th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of $2.54 per share for the quarter, up from their previous estimate of $1.98. HC Wainwright currently has a “Buy” rating and a $117.00 target price on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.46 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ Q3 2026 earnings at $2.88 EPS, Q4 2026 earnings at ($0.76) EPS and FY2026 earnings at $4.72 EPS.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.55. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. The company had revenue of $56.37 million for the quarter, compared to the consensus estimate of $11.70 million.

PTGX has been the topic of several other research reports. Johnson Rice restated a “buy” rating on shares of Protagonist Therapeutics in a report on Wednesday, March 18th. Jefferies Financial Group restated a “buy” rating and set a $121.00 price objective on shares of Protagonist Therapeutics in a report on Wednesday, March 18th. Leerink Partners boosted their price objective on shares of Protagonist Therapeutics from $107.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, March 19th. Barclays boosted their price objective on shares of Protagonist Therapeutics from $113.00 to $119.00 and gave the stock an “overweight” rating in a report on Thursday, March 19th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Protagonist Therapeutics in a research note on Friday. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Protagonist Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $113.69.

Protagonist Therapeutics Stock Performance

NASDAQ:PTGX opened at $98.37 on Wednesday. The firm’s 50-day moving average is $101.04 and its 200-day moving average is $90.89. Protagonist Therapeutics has a 52-week low of $44.72 and a 52-week high of $107.84. The company has a market cap of $6.33 billion, a price-to-earnings ratio of -54.35 and a beta of 1.89.

Institutional Trading of Protagonist Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE grew its stake in Protagonist Therapeutics by 49.3% during the first quarter. Bank of America Corp DE now owns 1,295,434 shares of the company’s stock worth $136,539,000 after buying an additional 427,854 shares during the last quarter. Stempoint Capital LP grew its stake in Protagonist Therapeutics by 22.1% during the first quarter. Stempoint Capital LP now owns 72,577 shares of the company’s stock worth $7,650,000 after buying an additional 13,147 shares during the last quarter. Janus Henderson Group PLC grew its stake in Protagonist Therapeutics by 9.1% during the first quarter. Janus Henderson Group PLC now owns 2,891,527 shares of the company’s stock worth $304,866,000 after buying an additional 241,546 shares during the last quarter. Amundi bought a new stake in Protagonist Therapeutics during the first quarter worth about $434,000. Finally, EverSource Wealth Advisors LLC grew its stake in Protagonist Therapeutics by 63.0% during the first quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $96,000 after buying an additional 352 shares during the last quarter. 98.63% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Harold E. Selick sold 24,000 shares of the company’s stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $105.00, for a total value of $2,520,000.00. Following the sale, the director owned 60,845 shares of the company’s stock, valued at $6,388,725. The trade was a 28.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Arturo Md Molina sold 15,000 shares of the company’s stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $104.79, for a total transaction of $1,571,850.00. Following the completion of the sale, the insider directly owned 84,115 shares in the company, valued at approximately $8,814,410.85. The trade was a 15.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 254,345 shares of company stock valued at $25,810,506 over the last 90 days. Company insiders own 5.19% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.